Uterine fibroids affect 70 to 80 percent of women by age 50. Only 25 to 30 percent of those women develop symptoms such as heavy bleeding or pelvic pressure. Detection methods range from transvaginal ultrasound with 87 percent sensitivity for larger fibroids to hysteroscopy that confirms intrauterine cases in every instance.
Key Takeaways
- Ultrasound detects fibroids in 70-90% of symptomatic women presenting with AUB
- Uterine fibroids (leiomyomas) are the most common benign tumors in women, affecting 70-80% of women by age 50 in the United States
- Obesity increases fibroid risk by 2-3 fold, with BMI >30 associated with 21% higher prevalence per 5-unit BMI increase
- Heavy bleeding (menorrhagia) affects 30-50% of women with fibroids, often >80mL blood loss per cycle
- Hysterectomy is performed in 99.5% effectiveness for symptom relief, but 20-30% complication rate including infection 5%
Fibroids are common, affecting many people, and their impact varies widely by size and symptoms.
Related reading
01 · Category
Diagnosis28 stats
01
Ultrasound detects fibroids in 70-90% of symptomatic women presenting with AUB
02
MRI sensitivity 88-100% for fibroid mapping, distinguishing from adenomyosis with 95% accuracy
03
Saline infusion sonohysterography (SIS) detects submucosal fibroids with 92% sensitivity vs hysteroscopy
04
Hysteroscopy visualizes intrauterine fibroids in 100% of cases, with biopsy accuracy 98%
05
Transvaginal ultrasound (TVUS) first-line, sensitivity 87% for fibroids >1cm, specificity 97%
06
Fibroid volume measured by ultrasound formula (length x width x height x 0.52) correlates 95% with pathology
07
CA-125 elevated >35 U/mL in 20-50% of large fibroids, mimicking ovarian cancer (false positive 15%)
08
3D ultrasound improves volume accuracy to 98% vs 2D 85%
09
Contrast-enhanced MRI shows enhancement patterns: 95% non-enhancing in leiomyosarcoma differentiation
10
Endometrial biopsy rules out hyperplasia in 95% of AUB cases with fibroids
11
Doppler US distinguishes pedunculated fibroids from adnexal masses with 90% accuracy
12
FIGO classification system applied in 85% of imaging reports for surgical planning
13
CT scan rarely used but detects calcification in 10-30% of fibroids
14
Elastography on US shows fibroids stiffer (shear wave >3m/s) vs myometrium 95% specificity
15
PET-CT for sarcoma suspicion: SUV max >5 in 80% malignancies vs <3 in benign
16
Office hysteroscopy detects 10-15% more submucosal fibroids than TVUS alone
17
Ultrasound criteria for sarcoma: rapid growth >30% in 6 months, sensitivity 60% specificity 95%
18
T2-weighted MRI: fibroids hypointense in 70%, hyperintense degenerate 20%
19
Blood flow velocity on Doppler: <40 cm/s typical for benign fibroids (95%)
20
Hyaluronic acid test for SIS improves submucosal detection to 98%
21
ADC values on DWI-MRI <1.4 x 10^-3 mm²/s suggest cellular fibroids, 90% accuracy
22
Pelvic exam detects >5cm fibroids in 60-70% of cases
23
GnRH agonist trial reduces fibroid volume 30-50% confirming diagnosis in ambiguous cases
24
HIFU eligibility assessed by MRI: posterior acoustic shadow in 85% suitable fibroids
25
Myometrial invasion depth measured by MRI >50% indicates higher surgical risk
26
Uterine artery embolization pre-procedure angiography confirms vascular supply in 100%
27
Symptom severity score (UFS-QOL) >50 correlates with fibroid volume >200cc on imaging
28
Laparoscopy confirms FIGO type 4-6 fibroids missed by US in 20% cases
Interpretation
Diagnosis Interpretation
From the initial probing of a transvaginal ultrasound to the definitive gaze of hysteroscopy, the diagnostics cascade reveals that while imaging offers an impressively precise map of fibroids—with MRI reigning supreme in differentiation and hysteroscopy holding the ultimate visual confirmation—the true clinical art lies in synthesizing these myriad tools, from saline sonography to Doppler flow, to accurately chart a path through symptoms, surgical planning, and the critical task of ruling out malignancy.
02 · Category
Epidemiology30 stats
01
Uterine fibroids (leiomyomas) are the most common benign tumors in women, affecting 70-80% of women by age 50 in the United States
02
Globally, uterine fibroids have a lifetime prevalence of up to 80% among reproductive-aged women, with higher rates in African ancestry populations
03
In the US, approximately 26 million women between ages 15-50 are affected by uterine fibroids annually
04
Black women have a 3-fold higher incidence of uterine fibroids compared to White women, with diagnosis occurring 2-3 years earlier on average
05
Prevalence of uterine fibroids increases with age, reaching 60% in women aged 35-49 years per ultrasound screening studies
06
Symptomatic fibroids affect about 25-30% of women with fibroids, leading to 200,000 hysterectomies yearly in the US
07
In a study of 632 women, fibroid prevalence was 41% overall, but 59% in Black women versus 24% in White women
08
Fibroids contribute to 33% of all hysterectomies performed in the US annually, totaling over 600,000 procedures
09
Lifetime risk of developing uterine fibroids is estimated at 70% for White women and over 80% for Black women
10
In autopsy studies, fibroid prevalence exceeds 70% in women over 40 years old
11
Fibroids are found in 5-10% of asymptomatic women via routine pelvic exams
12
Annual healthcare costs for fibroids in the US exceed $34 billion, including surgeries and lost productivity
13
Prevalence in Hispanic women is intermediate, at about 40-50% by age 50, between Black and White rates
14
Fibroids occur in 20-40% of women aged 35-44 years based on ultrasound data from primary care
15
In perimenopausal women, fibroid prevalence is around 40%, with many becoming asymptomatic post-menopause
16
Fibroids are detected in 51% of women undergoing hysterectomy for benign indications
17
Global burden includes 210 million women affected, with highest rates in sub-Saharan Africa over 80%
18
In the UK, 1 in 3 women develop fibroids, leading to 13,000 hysterectomies per year
19
Fibroid incidence peaks between ages 35-45, with cumulative incidence of 60% by age 45 in screening cohorts
20
Asian women have lower prevalence at 20-30% compared to 50-80% in African descent women
21
Fibroids account for 5% of infertility cases in reproductive-aged women
22
In a Finnish cohort, prevalence was 21% at age 30, rising to 74% at age 50 via MRI screening
23
US military women show 35% prevalence, higher in Black servicewomen at 52%
24
Fibroids detected in 40% of women seeking fertility treatment under age 35
25
Prevalence in adolescents is 1-5%, but symptomatic cases up to 10% in those with heavy bleeding
26
In Canada, 20-25% of women aged 20-49 have fibroids, per national health surveys
27
Fibroids contribute to 1.5% of pregnancy losses and 10% of preterm births indirectly
28
In Italy, ultrasound prevalence is 23% in premenopausal women, higher with age
29
Australian studies show 25% prevalence in women 40-49 years via pelvic imaging
30
In Japan, fibroid prevalence is 30-40% by MRI, lower hysterectomy rates due to cultural factors
Interpretation
Epidemiology Interpretation
This staggering data paints fibroids as a near-universal, often silent, tenant in the female reproductive system, yet one whose disruptive and costly eviction notices are disproportionately served to Black women, highlighting a profound and urgent health disparity.
03 · Category
Risk Factors24 stats
01
Obesity increases fibroid risk by 2-3 fold, with BMI >30 associated with 21% higher prevalence per 5-unit BMI increase
02
African ancestry is the strongest risk factor, with odds ratio (OR) of 2.9 for Black vs White women in meta-analyses
03
Early menarche (age <11) raises fibroid risk by 49% (OR 1.49, 95% CI 1.06-2.09)
04
Nulliparity increases risk by 30-50%, with each birth reducing odds by 14% (OR 0.86 per birth)
05
Family history doubles the risk (OR 2.0-2.5), with first-degree relatives showing 51% concordance
06
Hypertension is associated with 25-40% higher fibroid risk (OR 1.37, 95% CI 1.22-1.53)
07
Vitamin D deficiency (<20 ng/mL) linked to 32% increased odds (OR 3.2 in deficient vs sufficient)
08
High dietary red meat intake (>1 serving/day) raises risk by 50% (OR 1.5)
09
Oral contraceptive use reduces risk by 20-30% with long-term use (OR 0.71 for >10 years)
10
Smoking decreases risk by 25% in current smokers (OR 0.74, 95% CI 0.58-0.95)
11
Alcohol consumption >2 drinks/week increases risk by 50% (OR 1.5), especially beer
12
Age at first birth >30 years triples risk compared to <20 years (OR 3.0)
13
Dairy intake >3 servings/day protective, reducing risk by 30% (OR 0.70)
14
Genetic factors account for 28-52% heritability in twin studies
15
Estrogen-only HRT post-menopause increases risk by 40% (OR 1.38)
16
Low fruit/vegetable intake (<2 servings/day) associated with 20% higher risk
17
PCOS comorbidity raises fibroid odds by 2.5-fold (OR 2.5)
18
Caffeine >200mg/day increases risk by 20% (OR 1.20)
19
Physical inactivity (>20 hours sedentary/week) OR 1.47 for fibroids
20
Tamoxifen use for breast cancer doubles fibroid risk (OR 2.1)
21
High glycemic load diet (> median) increases risk by 58% (OR 1.58)
22
Uterine leiomyoma risk reduced 21% per 10g/day soy isoflavone intake
23
Diabetes mellitus type 2 associated with 1.6-fold risk (OR 1.64, 95% CI 1.25-2.14)
24
Parity >3 children protective, OR 0.52 compared to nulliparous
Interpretation
Risk Factors Interpretation
Your body appears to be running a comprehensive risk calculation for fibroids, factoring in everything from your ancestral roots and first period to your dinner plate and sofa time, which is why the only guaranteed preventive measure seems to be being born a different person with entirely different life choices.
More related reading
04 · Category
Symptoms25 stats
01
Heavy bleeding (menorrhagia) affects 30-50% of women with fibroids, often >80mL blood loss per cycle
02
Pelvic pain or pressure reported in 40% of symptomatic cases, worsening with fibroid size >5cm
03
Acute pain from degeneration occurs in 10-30% of pregnancies with fibroids
04
Bulk symptoms like urinary frequency in 40-60% when fibroids distort bladder
05
Infertility linked to submucosal fibroids in 5-10% of cases, distorting endometrial cavity
06
Dyspareunia (painful intercourse) in 20-30% of women with posterior fibroids >4cm
07
Anemia from chronic heavy bleeding affects 20-30%, with hemoglobin <10g/dL common
08
Constipation or bowel obstruction rare but in 5% with large fibroids >10cm compressing rectum
09
Abnormal uterine bleeding patterns: prolonged menses in 50%, intermenstrual spotting 20%
10
Fatigue due to anemia reported by 60% of women with heavy menstrual bleeding from fibroids
11
Backache or leg pain from radiculopathy in 10-15% with pedunculated or broad ligament fibroids
12
Increased urinary frequency/urgency in 33%, nocturia in 20% per quality-of-life studies
13
Pregnancy complications: 10-30% higher miscarriage risk with submucosal fibroids
14
Postmenopausal bleeding in 5-10% if fibroids persist and undergo necrosis
15
Abdominal distension or bloating in 50% with uteri >12-week gestation size
16
Headaches and dizziness from severe anemia (Hb<8g/dL) in 15% untreated cases
17
Sexual dysfunction score elevated 2-fold in UFS-QOL surveys for symptomatic women
18
Rectal pressure or tenesmus in 10% with posterior fibroids >6cm
19
Recurrent UTIs due to bladder compression in 8-12% of large fibroid cases
20
Emotional distress/depression scores 30% higher in symptomatic vs asymptomatic
21
Menstrual blood loss quantified at 200-500mL/cycle in 40% vs normal 30-40mL
22
Acute torsion of pedunculated fibroids causes severe pain in 1-2% of cases annually
23
Preterm labor risk increased 2-fold with fibroids >5cm in pregnancy
24
Reduced quality of life: SF-36 scores 20-40% lower in health domains
25
Polydipsia/polyuria mimic from bladder distortion in 5%
Interpretation
Symptoms Interpretation
While fibroids may sound like a mere statistical nuisance on paper, their lived reality is a visceral and often debilitating symphony of blood, pain, and exhaustion that hijacks a woman's body, dignity, and daily life.
05 · Category
Treatment28 stats
01
Hysterectomy is performed in 99.5% effectiveness for symptom relief, but 20-30% complication rate including infection 5%
02
Myomectomy preserves fertility: live birth rate 50-60% post-surgery in infertile women
03
UAE reduces fibroid volume 40-60% at 3 months, symptom relief in 85-90%
04
GnRH agonists shrink fibroids 30-64% in 3-6 months, but only 50% symptom relief long-term
05
Ulipristal acetate (5mg daily) reduces volume 20-40% in 3 months, 70% bleeding control
06
MRI-guided focused ultrasound (MRgFUS) non-invasive ablation: 70% volume reduction, 80% symptom improvement at 1 year
07
Levonorgestrel IUS reduces bleeding 70-90% in women with submucosal fibroids <3cm
08
Radiofrequency ablation (Acessa) shrinks 60-80%, 85% satisfaction at 3 years
09
Combined oral contraceptives control bleeding in 60-70% mild cases
10
Tranexamic acid reduces blood loss 40-60% during menses, safe for long-term use
11
Laparoscopic myomectomy recurrence 15-20% at 5 years vs 27% abdominal
12
Relugolix combination therapy: 73% amenorrhea at 6 months, 80% volume reduction
13
NSAIDs relieve pain in 70%, but no volume effect
14
Hysteroscopic resection for type 0-1 fibroids: 90% success, recurrence 15% at 5 years
15
Linzagolix (SPR094104) phase 3: 80% heavy bleeding reduction, well-tolerated
16
Cryomyolysis laparoscopic: 65% volume reduction, 75% symptom relief at 12 months
17
Progestin therapy (medroxyprogesterone) controls bleeding 50-60%
18
Robotic myomectomy: blood loss <200mL average, hospital stay 1 day
19
Elagolix + add-back: 77% amenorrhea, bone loss <1% at 12 months
20
Watchful waiting: 30% spontaneous regression post-menopause
21
Vitamin D supplementation 50,000 IU/week reduces volume 20-30% in deficient patients
22
Acupuncture trials show 40% symptom reduction vs sham
23
Green tea extract (EGCG 800mg/day): 32% volume reduction at 4 months
24
Mifepristone 10mg daily: 50% volume decrease, 70% bleeding control
25
UAE reintervention rate 15-20% at 5 years, pregnancy rate post 30-40%
26
Letrozole 2.5mg daily: 35% shrinkage, alternative for pre-surgical
27
Iron supplementation corrects anemia in 90% within 3 months adjunct therapy
28
MRgFUS NPV >200 no-go zones: 60% eligible, re-treatment 20%
Interpretation
Treatment Interpretation
Navigating fibroid treatment options is a masterclass in trade-offs, where choosing between the definitive finality of a hysterectomy and the hopeful preservation of fertility procedures requires weighing stellar success rates against sobering complication statistics, a delicate balancing act between eradicating symptoms now and preserving possibilities for later.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Alexander Schmidt. (2026, February 13). Fibroids Statistics. Gitnux. https://gitnux.org/fibroids-statistics
MLA
Alexander Schmidt. "Fibroids Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/fibroids-statistics.
Chicago
Alexander Schmidt. 2026. "Fibroids Statistics." Gitnux. https://gitnux.org/fibroids-statistics.
Sources & references
15 datasets cited across this report · attribution is report-level